In June 2026, EU food safety regulators approved sales of a GLP-1-inducing food additive, a change which may lead to 'supercharged' cereals and breads in Europe within a year. (Free w/email.)

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Semaglutides, which belong to a class of drugs called GLP-1s, are prescribed for weight loss in combination with diet and exercise because they trigger the release of the appetite-suppressing hormone incretin.

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

GLP-1 helps reduce obesity through a number of mechanisms

Clinical studies show GLP-1 drugs, including semaglutide, promote weight loss through a number of effects. These include reduced appetite, slower emptying of the digestive tract, increased insulin production, and more.

GLP-1 drugs mimic a natural hormone that triggers appetite-suppressing effects

Ozempic, one of the brand names for the drug semaglutide, was originally developed in 2012, to help treat Type 2 diabetes. Among other effects, the drug mimics a naturally produced hormone known as GLP-1, which is released while eating to let our bodies know we are full.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

When people stopped using GLP-1, they regained two-thirds of the weight back

Research from 2022 found that when people stopped using the injectable form of the medication, they regained up to two-thirds of lost weight within a year. The finding suggests ongoing treatment will be required for weight loss.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

GLP-1s may lower inflammation, possibly helping to combat cognitive decline

An analysis of existing GLP-1 research, published in April 2025, indicated that GLP-1 drugs reduce inflammation, with numerous health benefits. The work notes that GLP-1s were linked with a statistically significant reduction in dementia in randomized clinical trials.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for)

Glucagon-like peptide-1, or GLP-1, is one of the most well-known peptides in common use. In 2024, 26.5% of all adults with diagnosed diabetes used the substance. GLP-1 was particularly popular among people with diabetes aged 50-64, followed by younger adults and then seniors aged 65+.

GLP-1s are netting interest for treating autoimmune diseases, but are considered experimental

Already used to treat type 2 diabetes, the novel medications are showing some early promise in experimental studies at reducing inflammation and treating autoimmune conditions including rheumatoid arthritis and inflammatory bowel conditions. But researchers caution that side effects are still under investigation—rarely the medication has caused lupus, an autoimmune disease.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

Saccharin was banned in Canada in the 1970s, but regulators may allow its use once again

The product, commonly known as Sweet'N Low, was banned in Canada in the late 1970s due to research indicating that the sweetener could cause cancer in lab rats. Subsequent studies have found that the rodent findings didn't hold true for humans, and so Canadian regulators state that they are considering updating their stance to allow the product to be added to certain foods (the product is currently allowed in the US).

Weight Watchers began offering access to GLP-1 weight-loss medications in 2023 after losing more than 1.5 million members over the previous two years.

Fake sugars may disrupt metabolic health

Alternative sweeteners such as stevia and sucralose are 100 times sweeter than common table sugar. New research suggests these "high-intensity" sweeteners significantly disrupt the composition of the gut microbiome, affecting overall health. (Some users may encounter a paywall.)

GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva.

Insurance coverage for GLP-1s remains uneven, but Medicare began covering it in some instances in July 2026.

Tirzepatide: A GLP-1 drug that also acts on separate receptors to promote weight loss

Tirzepatide, like semaglutide, is a GLP-1 drug used in diabetes treatment and for weight loss. Unlike semaglutide, it also acts on glucose-dependent insulinotropic polypeptide receptors, proving a second route to reducing appetite as a means to treat diabetes and promote weight loss.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

How weight loss drugs could reduce obesity costs

A detailed analysis from finance giant ING finds semaglutide and other weight loss drugs could significantly drive down global costs stemming from heart disease and other health problems associated with obesity. The benefits will vary, depending on each country’s demographics and drug and healthcare costs.

How semaglutides are both better and worse than we know

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

The US FDA issued a 2025 warning about BPC-157 and other popular peptides that are marketed for various regenerative properties.

A collection of molecular gastronomy techniques, from flavored air to turning oils into powder

Soy lecithin can be blended with flavored mixtures, such as herbs and Parmesan, to produce edible bubbles, which can be frozen into a solid foam. Maltodextrin can be combined with liquid fats in a food processor to create light, flavorful powders.

Xylitol, a sugar alcohol, is sometimes added to foods at 1,000 times the level seen naturally in foods

This article covers the latest research in sugar alcohols and heart health. Some work indicates that after consuming sugar alcohols erythritol or xylitol people are at an elevated risk of developing blood clots, which can cause heart attacks and strokes. Both substances occur in low levels naturally in fruits and vegetables and are also produced by the human body, but as sweeteners in foods they are present at exponentially higher levels.

Ultra-processed foods are made to maximize cravings and encourage overeating

Often disguised as healthy options like granola bars and low-fat yogurt, these foods silently fuel chronic diseases, despite dominating diets. Reviewing labels for ingredients like stabilizers and emulsifiers can serve as indicators to help identify these products.

Artificial sweeteners may disrupt gut health, throwing off the balance of beneficial bacteria in the gut and shifting the composition of the microbiome.

The dietary market is worth more than $60B

Listen to this question and answer session with the US Food and Drug Administration about dietary supplements—vitamins, minerals, probiotics and similar products people may buy in liquid, pill, or powder form. They are categorized legally as a category of food and can be legally brought to market without the FDA even knowing about it, though consumers can tell FDA about issues with the products and FDA can take action to remove dangerous or unlawful items after they're available.

Can you microdose GLP-1 agonists like Ozempic?

GLP-1 agonists like Ozempic can help with weight loss, diabetes, and anti-inflammation. For some users, normal doses are too much. So, they've started "microdosing"—taking a smaller amount than the lowest increment of the drug available. While not yet backed by clinical trials, some doctors observed positive effects for certain people.